Cardiogenic Shock
From Anvita Health Wiki
Contents |
Introduction
- Failure to maintain adequate perfusion of vital organs secondary to impaired myocardial function.
Etiology
- myocardial infarction
- hemodynamically significant arrhythmias
- cardiomyopathy
- acute valvular regurgitation ( papillary muscle rupture)
- acute ventricular septal defect (post MI)
- severe valvular stenosis
- acute coronary vasospasm
- rupture of free ventricular wall
- congenital heart disease with increased cardiac workload
Pathology
- elevated intracardiac pressure
- high cardiac filling pressures
- pulmonary artery wedge pressure > 18 torr
- depressed cardiac output
- cardiac index < 2.0 liters/min/m2
- increased systemic vascular resistance
- decreased mean arterial blood pressure - < 60 torr
Laboratory
Management
- initial goal is to maintain
- dobutamine: also causes peripheral vasodilation
- dopamine
- norepinephrine may be most prudent choice [4]
- controversy over which agent 1st line [4]
- identify & treat precipitating factors
- intra-aortic balloon counterpulsation
- PCI vs CAPG (early) [see SHOCK trial]
More General Terms
Additional Terms
- dobutamine (Dobutrex)
- Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial
References
- Manual of Medical Therapeutics, 28th ed, Ewald & McKenzie (eds), Little, Brown & Co, Boston, 1995, pg 135-36
- Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 211-214
- Medical Knowledge Self Assessment Program (MKSAP) 14, American College of Physicians, Philadelphia 2006
- De Backer D et al Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010 Mar 4; 362:779 PMID: [1]
- Levy JH. Treating shock - Old drugs, new ideas. N Engl J Med 2010 Mar 4; 362:841. PMID: [2]
